BofA/Merrill Lynch Upgrades Perrigo Co. (PRGO) to Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
Go back to BofA/Merrill Lynch Upgrades Perrigo Co. (PRGO) to Neutral
November 10, 2016 1:56 AM EST
DUBLIN, Nov. 10, 2016 /PRNewswire/ --Â
Delivered third quarter GAAP ("reported") net sales of $1.4 billion and non-GAAP ("adjusted") net sales of $1.3 billion, excluding sales of $22 million from held-for-sale businesses*
Delivered third quarter reported net loss of $1.3 billion and reported diluted loss per share of $8.76, driven by goodwill impairment charge of $804Â million and brand intangible assets impairment charge of $866Â million; delivered third quarter reported gross margin of 37.4%, and third quarter reported operating margin of (111.8)%
Realized adjusted net income of $236Â million and adjusted diluted earnings per share of $1.65; achieved third quarter adjusted gross margin of 47.5%...
More
November 10, 2016 1:56 AM EST
DUBLIN, Nov. 10, 2016 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO; TASE) today announced that as part of its ongoing business portfolio review, the Company will review strategic alternatives for the rights to the royalty stream from sales of the multiple sclerosis drug Tysabri® (natalizumab).
Perrigo's CEO John T. Hendrickson stated, "We continue to make progress on and take action against our stated strategic and operational plans first outlined in April 2016. Tysabri® dramatically improves the quality of life of patients with multiple sclerosis and its... More
